drugset / Trial / NCT04910100
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
Phase 2
Completed
226 enrolled
Betaliq, Inc.
Summit Analytical LLC · collabTrial Runners, LLC · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).
Timeline
- Start
- 2021-04-15
- Primary completion
- 2022-03-31
- Completion
- 2022-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nebivolol | Other / unclassified | 0.5 % | Topical |
| Subject | Nebivolol | Other / unclassified | 1 % | Topical |
| Subject | Timolol | Other / unclassified | 0.5 % | Topical |